RecruitingPhase 1NCT07171034
A Phase I Study of KLA318-2 Nanocrystal Injection
A Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of KLA318-2 Nanocrystal Injection in Healthy Participants
Sponsor
Hunan Kelun Pharmaceutical Co., Ltd.
Enrollment
48 participants
Start Date
Sep 1, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to evaluate the safety,tolerability and pharmacokinetics properties of KLA318-2 Nanocrystal Injection after a single intravenous injection in healthy participants.
Eligibility
Min Age: 18 YearsMax Age: 45 Years
Inclusion Criteria3
- Health participants (Age: 18~45 years);
- Body Weight: Male≥50.0kg, Female≥45.0kg; 18.5 ≤BMI≤ 28.0;
- Normal ECG, showing no clinically relevant deviations, as judged by the investigator.
Exclusion Criteria18
- Allergy or Drug hypersensitivity;
- Clinically significant Medical History;
- Gastrointestinal ulcers or gastrointestinal bleeding;
- History of any surgery within 4 weeks;
- History of any Medication within 14 days;
- History of any drug interactions with celecoxib within 30 days;
- History of any clinical study within 3 months;
- History of any vaccine within 1 month;
- History of any drug abuse, or positive drugs of abuse test result;
- Subjects with difficult venous blood collection/intolerance to venipuncture, or with a history of needle phobia/blood phobia;
- Massive blood loss (> 200 mL) in the past 3 months;
- Special requirements for diet;
- Heavy smoker ( more than 3 cigarettes/day) within 3 months;
- History of alcohol abuse,or heavy alcohol intake (more than 14 units a week) within 6 months, or positive alcohol test;
- Heavy caffeine intake;
- History of grapefruit, xanthine-rich foods intake within 7 days;
- Female participants are pregnant or lactating;
- History of unprotected sex within 2 weeks.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGKLA318-2 Nanocrystal Injection
Intravenous injection, single dose
DRUGCelebrex Capsule
P.O., single dose
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07171034
Related Trials
A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity
NCT070136432 locations
A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1043 in Healthy Adult Participants Living With Overweight and/or Obesity.
NCT075112053 locations
Location- and Frequency-Dependent Effects of Thalamic Temporal Interference Stimulation During Sleep
NCT074982701 location
A Study to Assess the Effect of AZD0780 on the Pharmacokinetics of AZD4954 and Vice Versa in Healthy Adults
NCT075135711 location
Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel)
NCT075390901 location